Table 1.
Baseline characteristics of patients with cN3M0 esophageal cancer
| All patients (n = 359), n (%) | |
|---|---|
| Sex | |
| Male | 266 (74.1) |
| Age, median (IQR) | 67 (60–73) |
| Tumor type | |
| Adenocarcinoma | 235 (65.5) |
| Squamous cell carcinoma | 104 (29) |
| Missing | 20 (5.6) |
| Tumor differentiation grade | |
| Well differentiated (G1) | 11 (3.1) |
| Moderately differentiated (G2) | 86 (24) |
| Poor differentiated (G3) | 124 (34.5) |
| Missing | 138 (38.4) |
| Clinical T category | |
| cTx | 17 (4.7) |
| cT1 | 3 (0.8) |
| cT2 | 44 (12.3) |
| cT3 | 250 (69.6) |
| cT4 | 45 (12.5) |
| Treatment | |
| None | 33 (9.2) |
| Chemotherapy | 34 (9.5) |
| Chemoradiotherapy | 90 (25.1) |
| Radiotherapy | 44 (12.3) |
| Chemotherapy and surgery | 14 (3.9) |
| Chemoradiotherapy and surgery | 110 (30.6) |
| Surgery alone | 14 (3.9) |
| Missing | 20 (5.6) |
IQR, interquartile range.